[go: up one dir, main page]

DE60137146D1 - Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten - Google Patents

Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Info

Publication number
DE60137146D1
DE60137146D1 DE60137146T DE60137146T DE60137146D1 DE 60137146 D1 DE60137146 D1 DE 60137146D1 DE 60137146 T DE60137146 T DE 60137146T DE 60137146 T DE60137146 T DE 60137146T DE 60137146 D1 DE60137146 D1 DE 60137146D1
Authority
DE
Germany
Prior art keywords
diseases
treatment
fusion cells
fusion
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60137146T
Other languages
English (en)
Inventor
Tsuneya Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60137146D1 publication Critical patent/DE60137146D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60137146T 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten Expired - Fee Related DE60137146D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24215400P 2000-10-20 2000-10-20
PCT/US2001/047057 WO2002032378A2 (en) 2000-10-20 2001-10-22 Fusion cells and cytokine compositions for treatment of disease

Publications (1)

Publication Number Publication Date
DE60137146D1 true DE60137146D1 (de) 2009-02-05

Family

ID=22913659

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137146T Expired - Fee Related DE60137146D1 (de) 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Country Status (9)

Country Link
US (2) US20020168351A1 (de)
EP (1) EP1368061B1 (de)
JP (1) JP2004511503A (de)
AT (1) ATE418344T1 (de)
AU (2) AU2002225990B2 (de)
CA (1) CA2426366A1 (de)
DE (1) DE60137146D1 (de)
IL (1) IL155514A0 (de)
WO (1) WO2002032378A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
EP1509594A1 (de) * 2002-05-31 2005-03-02 Apollo Life Sciences Pty Ltd. Elektrofusion von zellen und vorrichtung dafür
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
WO2005083062A1 (ja) * 2004-02-26 2005-09-09 Genomidea Inc. 細胞ワクチン
CA2558382A1 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
US7225078B2 (en) * 2004-11-03 2007-05-29 Halliburton Energy Services, Inc. Method and system for predicting production of a well
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2010058023A1 (en) 2008-11-24 2010-05-27 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity t cell receptor and use thereof
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049803A (en) * 1976-04-26 1977-09-20 Bristol-Myers Company Augmentation of blood levels of aspirin
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
ATE388237T1 (de) * 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2001062902A1 (en) * 2000-02-27 2001-08-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybrid cell vaccines
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
CA2558382A1 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer

Also Published As

Publication number Publication date
WO2002032378A3 (en) 2003-02-27
JP2004511503A (ja) 2004-04-15
AU2599002A (en) 2002-04-29
EP1368061A2 (de) 2003-12-10
IL155514A0 (en) 2003-11-23
EP1368061A4 (de) 2005-10-19
US20020168351A1 (en) 2002-11-14
AU2002225990B2 (en) 2007-07-19
CA2426366A1 (en) 2002-04-25
EP1368061B1 (de) 2008-12-24
ATE418344T1 (de) 2009-01-15
WO2002032378A9 (en) 2003-06-26
WO2002032378A2 (en) 2002-04-25
US20040028663A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE355288T1 (de) Verbindungen und therapeutische methoden
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
EP1556513A4 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
BR0015597A (pt) Uso de anticorpos como vacinas
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
EP1037918A4 (de) Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
MY127452A (en) Vaccines.
MA27474A1 (fr) Vaccin
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
PT1150981E (pt) Composto nucleosidico terapeutico
ATE464064T1 (de) Aktivierung antigen-spezifischer t-zellen mit virus/antigen-behandelten dendritischen zellen
UA29106A (uk) Спосіб лікування вібраційної хвороби
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee